Cargando…
Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
BACKGROUND: Neuromyelitis optica (NMO) is a severe inflammatory autoimmune disorder of the central nervous system and often results in paralysis or blindness. Rituximab (RTX) is a mouse–human chimeric monoclonal antibody specific for the CD20 antigen on B lymphocytes and used to treat many autoimmun...
Autores principales: | Gao, Fulin, Chai, Bingyan, Gu, Cheng, Wu, Ruipeng, Dong, Tong, Yao, Yuping, Zhang, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402122/ https://www.ncbi.nlm.nih.gov/pubmed/30841862 http://dx.doi.org/10.1186/s12883-019-1261-2 |
Ejemplares similares
-
Vitamin D deficiency as a risk factor for dementia and Alzheimer’s disease: an updated meta-analysis
por: Chai, Bingyan, et al.
Publicado: (2019) -
Disease exacerbation after rituximab induction in neuromyelitis optica
por: Perumal, Jai S., et al.
Publicado: (2015) -
Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence
por: Etemadifar, Masoud, et al.
Publicado: (2017) -
Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience
por: Jade, Jui Dilip, et al.
Publicado: (2017) -
Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis
por: Wang, Hao, et al.
Publicado: (2021)